CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank83
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-25.45%
↑ 81% vs avg
Percentile
P83
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-135.90%
Historical baseline
PeriodValueYoY Change
TTM-25.45%-231.3%
202419.38%+555.2%
2023-4.26%+97.7%
2022-186.02%+38.8%
2021-303.75%-166.6%
2020-113.94%+34.5%
2019-174.05%-36.3%
2018-127.71%-118.0%
2017-58.59%+84.8%
2016-384.58%-